WisdomTree BioRevolution FundWDNA
WDNA
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
29% more capital invested
Capital invested by funds: $192K [Q2] → $247K (+$55.8K) [Q3]
1.9% more ownership
Funds ownership: 8.07% [Q2] → 9.97% (+1.9%) [Q3]
0% more funds holding
Funds holding: 3 [Q2] → 3 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for WDNA.
Financial journalist opinion
Positive
ETF Trends
2 weeks ago
Opportunities in Biotechnology Will Follow Advancements in the Science
By Christopher Gannatti, CFA Key Takeaways Recent advancements in GLP-1 drugs, such as Ozempic and Wegovy, underscore their potential to transform health care by addressing obesity, cardiovascular diseases and even neurodegenerative conditions.
Neutral
ETF Trends
11 months ago
Why We Loved Bill Gates's Annual Letter
By Christopher Gannatti, CFA, Global Head of Research We have been writing a lot about artificial intelligence (AI) and the ways in which we believe that topic will continue to evolve as the calendar changes from 2023 to 2024.
Positive
ETF Trends
1 year ago
Wager on WDNA for Biotech Rebound
It's been a lengthy of stretch of subpar performance by biotech stocks and related exchange traded funds. That's a scenario that will repeat this year.
Charts implemented using Lightweight Charts™